Psilocybin has gone from Schedule I punchline to one of the most studied compounds in psychiatry, and the podcast world caught on early. Scientists, mycologists, and journalists have spent hundreds of hours across shows like Huberman Lab, The Tim Ferriss Show, Lex Fridman, and Joe Rogan Experience explaining exactly what this molecule does to a brain, why it might treat depression better than an SSRI, and why nobody can fully explain the mushrooms themselves. We pulled the sharpest conversations from our full library of episode summaries.
This list runs from hard neuroscience (receptor binding, TMS circuits, clinical trial data) to the stranger edges of the psychedelic world (DMT-insensitive people, mushrooms on pyramid walls, fungi older than the breakup of Gondwana). Whether you want the clinical case for psilocybin therapy or just want to understand why some people feel nothing on massive doses, there's an episode here for it.
How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks
This is the episode to start with if you want the actual pharmacology explained in plain language. Huberman lays out how psilocybin converts to psilocin in the body, which resembles serotonin closely enough to selectively activate the serotonin 2A receptor and reduce the brain's normal hierarchical organization. He notes that psilocybin clinical trials are outperforming standard therapy and SSRIs for depression in ways he calls staggering to the psychiatric community, and explains why the visual cortex's dense 2A receptor expression causes hallucinations even with your eyes closed. Anyone who wants the neuroscience before the mythology should start here.
Read the full episode notesEssentials: Psychedelics & Neurostimulation for Brain Rewiring | Dr. Nolan Williams
Stanford's Nolan Williams argues the serotonin 'chemical imbalance' theory of depression is wrong, pointing out that his TMS protocol drives 60-90% of patients into remission without touching serotonin levels at all. He walks through how his Stanford Neuromodulation Therapy compresses six weeks of treatment into five days using spaced-learning theory, and describes patients who remit early spontaneously reporting mindfulness-like states they'd only read about. It's a companion piece to the psilocybin research, showing brain-circuit therapy converging on the same targets from a different direction. Listen if you want the brain-stimulation side of the psychedelic-adjacent story.
Read the full episode notesMatthew Johnson: Psychedelics | Lex Fridman Podcast #145
Johns Hopkins researcher Matthew Johnson gives the widest tour on this list, distinguishing classic psychedelics from MDMA and explaining why psilocybin and LSD are freakishly safe with no known lethal overdose dose for most people. He notes classic psychedelics are not addictive, unheard of among recreational drugs, and puts the danger of illegal drugs in perspective by naming nicotine as the deadliest substance by a wide margin. The detour into smoked DMT breakthroughs and Kary Mullis crediting psychedelics for helping him invent PCR makes this one of the richest single episodes in the genre. Best for listeners who want policy, pharmacology, and personal story in one sitting.
Read the full episode notesAn Ethnopharmacologist on Hallucinogens, Sex-Crazed Cicadas, and More | Dennis McKenna
Terence McKenna's brother and a career ethnopharmacologist, Dennis McKenna gets into territory most episodes skip, like why some people feel absolutely nothing from massive doses of DMT while being highly sensitive to 5-MeO-DMT, a mystery he says was never solved. He describes discovering 'vegetable television,' smoking ayahuasca vine bark alongside mushrooms to produce controllable waves of visions, and reveals that psilocybin has existed for at least 75 million years, likely evolving as an insect attractant. This is the episode for people who already know the basics and want the genuinely strange parts of the science.
Read the full episode notesJoe Rogan Experience #2347 - Paul Stamets
Stamets makes the maximalist case, arguing psilocybin should be free and government-funded because it would slash crime and national debt, and claims mushroom imagery appears in Egyptian pyramid carvings and early Christian art. He cites the Stoned Ape theory to explain a roughly 50% jump in human brain size over 200,000 years, and notes there are now 235 clinical studies on psilocybin registered at clinicaltrials.gov, up from essentially none 25 years ago. It's a sprawling, opinionated conversation, best for listeners who want the cultural and historical sweep alongside the science.
Read the full episode notesEssentials: Psychedelics for Treating Mental Disorders | Dr. Matthew Johnson
In this Huberman Lab conversation, Johnson draws the pharmacological map between serotonin 2A agonists like psilocybin and LSD, NMDA antagonists like ketamine, and entactogens like MDMA. He confirms rare but credible cases of people believing they could fly on psychedelics, notes that even with ideal preparation, about a third of people report a bad trip at some point during a therapeutic-dose session, and states there is no credible peer-reviewed evidence that microdosing actually works. Useful for anyone weighing the real risks against the therapeutic promise before deciding this is for them.
Read the full episode notesMichael Pollan: How To Change Your Mind | E158
The author of How to Change Your Mind talks with Steven Bartlett about the immersive reporting behind his psychedelics book, framing his own experiences alongside a wider argument that no drug offers a free lunch, including caffeine, which he explains blocks the neuromodulator adenosine so you 'borrow energy from the future.' The caffeine detour turns out to be one of the richest tangents on this list, noting a noon cup of coffee still has a quarter of its caffeine circulating at midnight. Good for readers who want a journalist's perspective on psychedelics rather than a researcher's.
Read the full episode notesThinking Differently About Addiction and Mental Health — Dr. Nora Volkow
NIDA director Nora Volkow brings the addiction-science lens to this list, describing her own experience of opioid withdrawal after a car accident as 'worse than pain' and identifying 2016 as the transformative shift when fentanyl entered the drug supply and made overdose deaths spike. She also discusses psychedelics and brain stimulation as emerging tools against addiction, drawing on her decades imaging the brains of drug users. Worth it for anyone who wants to understand psilocybin's therapeutic promise in the context of the broader addiction and overdose crisis.
Read the full episode notesJoe Rogan Experience #2134 - Paul Stamets
Stamets returns to detail his double-blind COVID trial showing Agarikon and Turkey Tail mushroom mycelium reduced adverse vaccine effects and extended antibody response six months out, then pivots into his psilocybin microdosing stack and mushrooms' place in ancient cultures. He notes he holds the world's largest Agarikon culture library, with 107 strains isolated and 95 whole-genome sequenced. This one is more mycology and immunity than pure psilocybin, but it's the clearest window into how Stamets connects fungi research to psychedelic medicine.
Read the full episode notesGiuliana Furci on the Wonders of Mycology, Wisdom from Jane Goodall, And More | The Tim Ferriss Show
Not a psilocybin episode directly, but essential context for understanding the fungal kingdom that produces it. Mycologist Giuliana Furci describes naming Amanita galactica, an 'elder species' dating back to when Gondwana still existed, and explains that fungi are more closely related to animals than to plants. Her account of founding the world's first fungi-focused nonprofit after finding no way to study mycology in Chile is a reminder of how young and underfunded fungal science still is. Listen for the wonder factor if you want a break from clinical trial data.
Read the full episode notesThat's ten conversations spanning the clinical trial data, the brain circuitry, and the stranger corners of mycology that make psilocybin one of the most-discussed compounds in podcasting right now. Browse the full episode summaries on Episode Notes for more from these guests and dozens of other psychedelics researchers.